Source - LSE Regulatory
RNS Number : 9482R
Creo Medical Group PLC
01 November 2023

Creo Medical Group plc

("Creo", the "Group" or the "Company")

Speedboat® UltraSlim: US FDA Clearance


Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, is pleased to announce that it has received 510(k) clearance from the US Food & Drug Administration ("FDA") for its Speedboat® UltraSlim device.


FDA clearance allows the Company to initiate the launch of UltraSlim in the USA through its existing direct sales force and supported by its network of key opinion leaders and clinicians. Clearance follows recent guidance received from the Company's notified body of an EU regulatory pathway which has accelerated the European launch of the UltraSlim device by approximately 18 months.


Speedboat® UltraSlim is the second brand in Creo's Speedboat® family of devices alongside Speedboat Inject and offers a number of different features. The primary feature is the reduced size in comparison with the Speedboat Inject. This results in the device being compatible with all endoscopes with a 2.8mm working channel or larger, accounting for the vast majority of GI endoscopic procedures and significantly increasing the opportunity for more clinicians and patients to benefit from Creo's cutting-edge technology.


The UltraSlim device is targeting the therapeutic treatment of Gastrointestinal ("GI") tract lesions (including Bowel and Upper GI cancers, and pre-cancerous lesions) and swallowing disorders. Powered by Creo's CROMA advanced energy platform, the UltraSlim delivers advanced bi-polar Radiofrequency ("RF") energy for controlled cutting and high frequency microwave ("MW") energy for controlled coagulation of tissue in the GI tract.


Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted to receive FDA clearance for Speedboat UltraSlim, which is testament to the hard work of our entire team. Our engineering team have overcome many challenges to scale the Speedboat technology down to the size of the UltraSlim, and, with the support of our regulatory team, we have been able to obtain FDA clearance with speed and efficiency.


"Together with the recent news of the accelerated regulatory pathway in the EU, we look forward to patients, clinicians and healthcare providers being able to benefit from the widespread commercialisation of Speedboat UltraSlim in both Europe and the US in 2024 and beyond."




Creo Medical Group plc

Richard Rees (CFO)

+44 (0)1291 606 005

Cavendish Capital Markets Limited

+44 (0)20 7220 0500

Stephen Keys / Camilla Hume (NOMAD)

Nigel Birks / Harriet Ward (Corporate Broking)

Michael Johnson (Sales)

Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Euan Brown

+44 (0)20 7260 1000


Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or

Paul McManus / Sam Allen /

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 



About Creo Medical


Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.


The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.



For more information, please refer to the website

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Creo Medical Group PLC (CREO)

-0.25p (-0.75%)
delayed 15:57PM